However, supporting studies have shown that AKT inhibition by the PI3K inhibitor LY-294002 or the PI3K/mTor inhibitor NVP-BEZ can down-regulate the CD133 expression in colorectal cancer cell-lines [61] and prostate cancer [62]. This evidence concerns the gene PROM1 and prostate cancer.